SMO and glioma: Unfortunately, in some tumors, including medulloblastoma, glioma, pericytoma, prostate, and breast cancer, there are many alternative mechanisms for HH signaling activation through Smo downstream effectors, making Smo inhibitors ultimately ineffective.